Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Eisai Divests Contract Manufacturing Biz | Contract Pharma

What are you searching for?

Sign in
Breaking News

Eisai Divests Contract Manufacturing Biz

Alfresa strengthens manufacturing ops with acquisition of Sannova

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Japanese drug giant Eisai has entered into a business acquisition agreement with Alfresa Holdings Corporation concerning the splitting off of Eisai’s consolidated pharmaceutical manufacturing and marketing subsidiary Sannova. The effective date of the split is scheduled to be March 31, 2016.

Sannova produces a variety of formulations such as granules, powders, tablets, liquids, ointments, creams and lotions of prescription pharmaceuticals, generics, over the counter pharmaceuticals and quasi-drugs.

Alfresa Holdings says it is working to strengthen its pharmaceutical contract manufacturing business centered on its wholly-owned subsidiary Alfresa Pharma Corporation.

Eisai says it will continue to commission the new company who will succeed the business of Sannova via absorption-type split to manufacture Eisai Group products currently manufactured by Sannova, and maintain a cooperative relationship with this new company.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics